Recent advances in therapeutic cancer vaccines

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 1, 2012, Pages 2-5

  Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELAGENPUMATUCEL L; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EMEPEPIMUT S; GP100 PEPTIDE VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN 3; NAVELBINE; PEPTIDE VACCINE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CANCER CONTROL; CANCER GRADING; CANCER IMMUNIZATION; CANCER RESEARCH; CANCER SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; MELANOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS;

EID: 84856859415     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1200     Document Type: Review

References (51)

1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010;363:411.
2. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670.
3. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099.
4. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011;29:2787.
5. Freedman A, Neelapu SS, Nichols C, et al. Placebocontrolled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009;27:3036.
6. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119.
7. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV nonsmall- cell lung cancer. J Clin Oncol 2005;23:6674.
8. Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience. Lung Cancer 2011;73:11.
9. Nemunaitis J, Nemunaitis M, Senzer N, et al. Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non-small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009;16:620.
10. Vansteenkiste J, Zielinski H, Linder A, et al. Final results of a muilti-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage Ib/II nonsmall cell lung cancer (NCSLC) [abst]. J Clin Oncol 2007; 25(suppl18).
11. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrateresistant prostate cancer. Cancer Immunol Immunother 2010;59:663.
12. Stein WD, Gulley JL, Schlom J, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011;17:907.
13. von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181.
14. von Mehren M, Arlen P, Tsang KY, et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 2000;6:2219.
15. Docetaxel and prednisone with or without vaccine therapy in treating patients with metastatic hormone-resistant prostate cancer. Online document at www.clinicaltrials.gov/ct2/ show/NCT01145508?term = McNeel = 5 Accessed on December 26, 2011.
16. Bristol JA, Schlom J, Abrams SI. Persistence, immune specificity, and functional ability of murine mutant ras epitopespecific CD4( + ) and CD8( + ) T lymphocytes following in vivo adoptive transfer. Cell Immunol 1999;194:78.
17. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711.
18. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167.
19. Kline J, Gajewski TF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs 2010;11:1354.
20. Chakraborty M, Schlom J, Hodge JW. The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. Cancer Immunol Immunother 2007;56:1471.
21. Madan RA, Mohebtash M, Arlen PM, et al. A phase I trial of ipilimumab and a poxviral vaccine targeting PSA inmetastatic castration-resistant prostate cancer: analysis of toxicity, response, and survival. Lancet Oncol. Accepted for publication.
22. van den Eertwegh AJM, Versluis J, van den Berg HP, et al. A phase I trial of combined immunotherapy with granulocyte- macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) and ipilimumab in patients with metastatic castration-resistant prostate cancer. Lancet Oncol. Accepted for publication.
23. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011;10:417.
24. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011;32:19.
25. Gajewski TF. Failure at the effector phase: Immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007;13:5256.
26. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006;213:131.
27. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006;29:233.
28. Kepp O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011;30:61.
29. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29:482.
30. Zitvogel L, Kepp O, Senovilla L, et al. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010;16:3100.
31. Chakraborty M, Abrams SI, Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64:4328.
32. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: Effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14:3536.
33. Gelbard A, Garnett CT, Abrams SI, et al. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res 2006;12:1897.
34. Emens LA, Asquith JM, Leatherman JM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colonystimulating factor-secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009;27:5911.
35. Gameiro SR, Caballero JA, Higgins JP, et al. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccinemediated antitumor responses. Cancer Immunol Immunother 2011;60:1227-1242.
36. Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 2011 Jun 1. Epub ahead of print.
37. Farsaci B, Sabzevari H, Higgins JP, et al. Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer 2010;127:1603.
38. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14: 6674.
39. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148.
40. Arredouani MS, Tseng-Rogenski SS, Hollenbeck BK, et al. Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate 2010;70:1002.
41. Lee DK, Hakim FT, Gress RE. The thymus and the immune system: Layered levels of control. J Thorac Oncol 2010;5:S273.
42. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 2001;98:14565.
43. Bilusic M, Gulley J, Heery C, et al. A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer [abst]. J Clin Oncol 2011;29(suppl7).
44. Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008;14:4526.
45. Sanda MG, Smith DC, Charles LG, et al. Recombinant vaccinia- PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 1999;53:260.
46. Dhodapkar KM, Feldman D, Matthews P, et al. Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A 2010;107:8718.
47. Fernando RI, Litzinger M, Trono P, et al. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest 2010;120:533.
48. Hua W, Yao Y, Chu Y, et al. The CD133 + tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma. J Neurooncol 2011 Apr 11.E-pub ahead of print.
49. Mine T, Matsueda S, Li Y, et al. Breast cancer cells expressing stem cell markers CD44 + CD24 lo are eliminated by Numb- 1 peptide-activated T cells. Cancer Immunol Immunother 2009;58:1185.
50. Palena C, Polev DE, Tsang KY, et al. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 2007;13:2471.
51. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265.